The USFDA issued six observations to Granules India’s Gagillapur facility in Hyderabad after an inspection between August 26 and September 6. The company is committed to addressing these issues promptly and will submit its response within the stipulated time frame. Following this news, Granules India’s stock fell by over 16% on the BSE.
The Headlines – Business News: Latest News on Business, Stock Markets, Financial News, India Business & World Business News – Read More